Dollar Tree, Inc. vs McKesson Corporation — how do they compare? Dollar Tree, Inc. trades at $117.94 (market cap $22.26B), while McKesson Corporation trades at $933.58 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 4.9× Dollar Tree, Inc.'s market cap, and McKesson Corporation pays a 0.4% dividend while Dollar Tree, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dollar Tree, Inc. for 58 Days and McKesson Corporation for 74 Days on average.
| DLTR | MCK | |
|---|---|---|
Market Cap | $22.26B | $108.46B |
Volume | 2,317,428 | 712,607 |
Sector | Consumer Staples | Health |
52-Week High | $141.21 | $995.69 |
52-Week Low | $86.80 | $725.17 |
Typical Hold Time | 58 Days | 74 Days |
Enterprise Value | $28.87B | $115.00B |
Dividend Yield | — | 0.4% |
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $116.30, up 0.09% with a bullish technical signal despite bearish moving averages. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $2.70 beating expectations of $1.15. Revenue trends show recovery from 2025's $17.58B to projected $20.1B in 2026, while net income rebounds from -$3.03B to projected $1.6B. Analyst consensus is bullish with 53% buy ratings and $139.33 price target, representing 20% upside potential.
DLTR presents a compelling investment case with improving fundamentals and positive earnings momentum, though margin pressures and tariff volatility remain key risks. The stock's attractive valuation (P/E 14.54, EV/EBITDA 9.91) combined with strategic initiatives and store expansions support growth outlook, but investors should monitor cost inflation and competitive pressures in the discount retail sector.
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →